Prostate Cancer Clinical Trials Near You

Prostate cancer clinical trials in 2026 span the full spectrum from active surveillance to metastatic castration-resistant disease. PSMA-targeted therapies are the most significant innovation: lutetium-177 PSMA (Pluvicto) demonstrated improved survival in metastatic CRPC, and trials are now testing PSMA-targeted agents earlier — in hormone-sensitive metastatic disease and even high-risk localized prostate cancer before surgery.

PARP inhibitors (olaparib, rucaparib, niraparib) are established for BRCA-mutated prostate cancer, with combination trials testing PARP + anti-androgen therapy (enzalutamide, abiraterone) in broader populations beyond BRCA-mutated tumors. Homologous recombination deficiency (HRD) testing is becoming routine to identify patients most likely to benefit.

Bispecific T-cell engagers and CAR-T cell therapies targeting PSMA are in early-phase trials for metastatic CRPC. These immunotherapy approaches are especially promising for patients who have progressed on androgen receptor signaling inhibitors and taxane chemotherapy.

For early-stage disease, focal therapy trials (HIFU, cryotherapy, irreversible electroporation) are testing whether treating only the tumor focus within the prostate can achieve cancer control while preserving urinary continence and sexual function — avoiding the side effects of whole-gland treatment.

Patient considerations: Prostate cancer trials stratify by Gleason score, PSA level, and metastatic burden. Ask your oncologist about comprehensive genomic testing — mutations in BRCA2, ATM, CDK12, and DNA repair genes may qualify you for targeted therapy trials. Expect regular PSA monitoring, imaging (CT, bone scan, PSMA-PET), and quality-of-life assessments (urinary, sexual, bowel function).